K Number
K984231
Device Name
ANGIOGRAPHIC CONTRAST MANAGEMENT SYSTEM, MODEL PART A AND PART B
Manufacturer
Date Cleared
2000-05-31

(553 days)

Product Code
Regulation Number
870.1650
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Acist™ CMS-2000 Angiographic Injection System with Contrast Management is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures.
Device Description
The ACIST Medical Systems Angiographic Contrast Management System is an accessory to the ACIST Injection System. It is designed to allow the user to safely use contrast media for multiple procedures . It consists of a two-park kit—Parts A, a non-patient contact kit, and B, a patient contact kit. Part A is initially set up and filled with contrast media. Part B is then attached to Part A via a connector and the system is ready to initiate a procedure. " The Drish attached it Part R VILLE Collection of the procedure, Part B is disconnected and discarded. The syringe cap is placed on Part A to maintain sterility between procedures. The Angiographic Contrast Management System is provided sterile and is intended for single use only.
More Information

Not Found

No
The summary describes a mechanical system for managing contrast media and does not mention any AI/ML components or functions.

No
The device is used for the controlled infusion of radiopaque contrast media, which is a diagnostic agent, not a therapeutic agent. It assists in imaging procedures rather than treating a disease or condition.

No
The device is described as an "Angiographic Injection System" and "Contrast Management System" intended for the "controlled infusion of radiopaque contrast media for angiographic procedures." Its purpose is to deliver contrast, not to diagnose.

No

The device description explicitly details physical components (two-part kit, syringe cap, connectors) and mentions performance studies related to sterility, pressure testing of interconnects, and packaging validation, all indicative of a hardware-based medical device.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is for the "controlled infusion of radiopaque contrast media for angiographic procedures." This describes a device used during a medical procedure to administer a substance to a patient for imaging purposes.
  • Device Description: The description details a system for managing and delivering contrast media, with components that come into contact with the contrast media and the patient. This aligns with a medical device used for administration, not for testing samples in vitro.
  • Lack of IVD Characteristics: The description does not mention any of the typical characteristics of an IVD, such as:
    • Analyzing biological samples (blood, urine, tissue, etc.)
    • Detecting or measuring substances in those samples
    • Providing diagnostic information based on the analysis of samples

The device is clearly designed to facilitate the delivery of contrast media into the patient for imaging, which is a therapeutic or procedural function, not an in vitro diagnostic function.

N/A

Intended Use / Indications for Use

The Acist™ Injection System is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures. The Angiographic Contrast Management System allows the user to safely use contrast media for multiple procedures.

The Acist™ CMS-2000 Angiographic Injection System with Contrast Management is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures.

Product codes (comma separated list FDA assigned to the subject device)

DXT

Device Description

The ACIST Medical Systems Angiographic Contrast Management System is an accessory to the ACIST Injection System. It is designed to allow the user to safely use contrast media for multiple procedures . It consists of a two-park kit—Parts A, a non-patient contact kit, and B, a patient contact kit. Part A is initially set up and filled with contrast media. Part B is then attached to Part A via a connector and the system is ready to initiate a procedure. " The Drish attached it Part R VILLE Collection of the procedure, Part B is disconnected and discarded. The syringe cap is placed on Part A to maintain sterility between procedures.

The Angiographic Contrast Management System is provided sterile and is intended for single use only.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Biological Challenge tests were conducted demonstrating the ability of the device to maintain the sterility of the contrast media and syringe, allowing continued used of those components. Pressure testing verified the interconnect between Parts A and B. Packaging validation testing verified the modified packaging configuration.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K963882, K961794, K903493

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 870.1650 Angiographic injector and syringe.

(a)
Identification. An angiographic injector and syringe is a device that consists of a syringe and a high-pressure injector which are used to inject contrast material into the heart, great vessels, and coronary arteries to study the heart and vessels by x-ray photography.(b)
Classification. Class II (special controls). The device, when it is a non-patient contacting balloon inflation syringe intended only to inflate/deflate balloon catheters and monitor pressure within the balloon, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

0

K984231

510(k) SUMMARY General Information

Date PreparedNovember 23, 1998
ClassificationClass II
Trade NameAngiographic Contrast Management System
Common NameIntravascular Fluid Delivery Set
SubmitterACIST Medical System
10250 Valley View Road
Eden Prairie, MN 55344
612-941-3507
ContactKate Anderson
Manager, QA/Regulatory
Predicate DevicesAcist Injection System (K963882)
ACIST Medical Systems
Merit Contrast Management System (K961794)
Merit Medical Systems, Inc.
NAMIC Contrast Saving Delivery System (K903493)
North American Instrument Corporation, Angiographic System
Division

Device Description

The ACIST Medical Systems Angiographic Contrast Management System is an accessory to the ACIST Injection System. It is designed to allow the user to safely use contrast media for multiple procedures . It consists of a two-park kit—Parts A, a non-patient contact kit, and B, a patient contact kit. Part A is initially set up and filled with contrast media. Part B is then attached to Part A via a connector and the system is ready to initiate a procedure. " The Drish attached it Part R VILLE Collection of the procedure, Part B is disconnected and discarded. The syringe cap is placed on Part A to maintain sterility between procedures.

1

The Angiographic Contrast Management System is provided sterile and is intended for single use only.

Indication

The Acist™ Injection System is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures. The Angiographic Contrast Management System allows the user to safely use contrast media for multiple procedures.

Technological Characteristics

The Angiographic Contrast Management System is designed to prevent patient contacting fluids from contaminating the fluid contained within the dual port syringe and contrast media container. Like the predicate Merit and Namic products, the Angiographic Contrast Management System is designed with one-way check valves to prevent retrograde flow.

As with the Namic product, Biological Challenge tests were conducted demonstrating the ability of the device to maintain the sterility of the contrast media and syringe, allowing continued used of those components. Pressure testing verified the interconnect between Parts A and B. Packaging validation testing verified the modified packaging configuration.

Summary

In summary, the above listed predicate devices and the ACIST Angiographic Contrast Management System are substantially equivalent based on design, performance characteristics, and indications for use.

2

Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement. The text is in all capital letters and is evenly spaced around the circle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 3 1 2000

Mr. Carl M. Beaurline Vice President Quality Assurance/Regulatory Affairs Acist Medical Systems, Inc. 7450 Flying Cloud Drive, Suite 150 Eden Prairie, MN 55344

K984231) and K991103 Re: (

R9042017 and RS-2000 Angiographic Injection System with Contrast Management Regulatory Class: Class II DXT Product Code: November 25, 1998 and March 26, 1999 Dated: November 25, 1998 and April 1, 1999 Received:

Dear Mr. Beaurline:

We have reviewed your Section 510(k) notifications of intent to market we nave reviewed your beceiver on the determined the device is the device fereienced above and his marketed predicate devices substantlainy equivatine co-regary many 28, 1976, the enactment Marketed in Incerdate Seathernments or to devices that have been date of the Medical Device famakers' of the Federal Food,
reclassified in accordance with the provisions of the dovice reclassified in accordance with eno pro therefore, market the device, Drug, and Cosmeric Acc (nec). Iou may and the Act. However, you Subject to the general some that the medical devices you use as are responsible to decembine ther been determined as substantially components in the neve casion ification process (Section 510 (k) of equivalence under the premained with market prior to May 28, 1976, the Please note: If you enactment date of the Medical Device Amendments. enactment auce or the components in bulk (i.e., unfinished) and further parchase your acterilize) you must submit a new 510(k) before process (e.g., Secrific) your kit/tray. The general controls Incruding these components in jequirements for annual registration, provisions of the nec incruas beganism
listing of devices, good manufacturing practice, and labeling, and frocing or as as as a so adulteration.

If your device is classified (see above) into either class II (Special II your device 15 crassized (bot class to the subject to such Controls) of Class III (Frenailer of the major regulations affecting your device additional concerner of Federal Regulations, Title 21, Parts 800 ound in the oly equivalent determination assumes compliance to 895. co 653. A Jubstanced in that is that is a requirements, as set with the Ourlows of System Regulation (QS) for Medical Devices:

3

Page 2 - Mr. Carl M. Beaurline

General regulation (21 CFR Part 820) and that, through periodic QS inspections, FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notifications. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on the labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Sincerely yours,

Bunn E. Atuvenym

James E. Dillard III Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health

4

PART A - INDICATIONS FOR USE FORM

Page of

K984231 510(k) Number:

Device Name:

Acist™ CMS-2000 Angiographic Injection System with Contrast Management

Indications for Use:

The Acist™ CMS-2000 Angiographic Injection System with Contrast Management is intended to be used for the controlled infusion of radiopaque contrast media for angiographic procedures.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Christopher M. Kure for Dillard.

Prescription Use X (Per 21 CFR 801.109)

OR

Over-The-Counter Use (Optional Format 1-2-96)